PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 2336931

The dexamethasone provocative test: a predictive tool for glaucoma?

A Klemetti
View original source ↗Export metadata ↓

Abstract

A retrospective follow-up study of 134 patients (84 women and 50 men) tested for their responsiveness to topically administered corticosteroids was carried out. Of the 134 patients tested, 34 (25.4%) had a high response (IOP rise greater than or equal to 16 mmHg), 66 (49.3%) an intermediate (IOP rise 6-15 mmHg) and 34 (25.4%) a low response (IOP rise less than or equal to 5 mmHg) to topically administered 0.1% dexamethasone eye drops. Follow-up time varied from 5 to 15 years (mean 7.1 years). During the follow-up period 29 (21.6%) patients developed glaucoma. Of these, 9 (31.0%) were high responders and 7 (24.0%) had a low response to corticosteroids. Log-linear analysis showed no correlation between corticosteroid response and development of glaucoma in the study eye (SD = 0.232, DF = 2, P = 0.890), the control eye (SD = 1.234, DF = 2, P = 0.540) or both eyes (SD = 0.618, DF = 2, P = 0.734). At the final examination 75 patients (56%) had an IOP of greater than or equal to 22 mmHg. Of these ocular hypertensive patients 28 (37.3%) were high responders, and 15 (20%) had a low response to corticosteroids. Of the whole material of 134 patients 44 had a family history of glaucoma. Eleven (25.1%) of these were high responders and 14 (31.8%) low responders. Of the 29 patients who developed glaucoma 8 had a family history of glaucoma. Of these 3 were high responders and 3 low responders. The results indicate that the dexaprovocative test yielded relatively limited value in the screening of patients for glaucoma.

Explore related subjects

Administration, TopicalAdultAgedDexamethasoneFemaleFollow-Up StudiesGlaucomaHumansIntraocular PressureMaleMiddle AgedOcular HypertensionRetrospective StudiesVision ScreeningJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Klemetti. 1990. The dexamethasone provocative test: a predictive tool for glaucoma?. https://doi.org/10.1111/j.1755-3768.1990.tb01645.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Endosonographic and manometric evaluation of internal anal sphincter in patients with chronic anal fissure and its correlation with clinical outcome after topical glyceryl trinitrate therapy.

BACKGROUND AND AIMS: Anorectal pressure studies have demonstrated internal anal sphincter (IAS) hypertonia in patients with chronic anal fissure. It is unknown however, if these changes in IAS function are associated with any abnormality in sphincter morphology. The first aim was to investigate the clinical characteristics and the manometric and endosonographic findings of the IAS in a cohort of patients with chronic anal fissure. The second aim was to investigate the association between these findings and the outcome with topical Glyceryl trinitrate (GTN) therapy. MATERIALS AND METHODS: All patients who presented with chronic anal fissure from November 1999 to May 2004 were included after failure of conservative therapy. Anorectal manometry and anal endosonography were performed before treatment with 0.2% GTN ointment twice daily was initiated. Patients were evaluated after 8 weeks. RESULTS: One hundred and twenty-four patients (66 women, mean age, 45.2 +/- 14.8 years) were included. Hypertonia of the IAS was found in 84 (68%) patients. The mean maximum IAS thickness was 3.6 +/- 0.76 mm (1.6-5.5). An abnormally thick IAS, adjusted by age, was observed in 113 (91.1%) patients. We found no correlation between resting pressure and IAS thickness (r = 0.074; p = 0.41). At 8 weeks, 52 patients (42%) had healed with complete symptoms resolution. No statistically significant differences were observed when clinical features and manometric and endosonographic findings were compared between healing and no-healing fissures. CONCLUSION: The majority of patients with chronic anal fissure present an abnormally thick IAS. Clinical, manometric and endosonographic features had no association with outcome after GTN treatment.

Administration, Topical↗
PubMed2007

Topical use of antifibrinolytic agents reduces postoperative bleeding: a double-blind, prospective, randomized study.

OBJECTIVE: Postoperative bleeding is still one of the most common complications of cardiac surgery. Antifibrinolytic agents successfully reduce bleeding, but there are controversies concerning adverse effects after their systemic use. By topical application of antifibrinolytic agents in pericardial cavity, most of these effects are avoided. We compared the effects of topically applied aprotinin, tranexamic acid and placebo on postoperative bleeding and transfusion requirements. METHODS: In this single-center prospective, randomized, double-blind trial, 300 adult cardiac patients were randomized into three groups to receive one million IU of aprotinin (AP group), 2.5g of tranexamic acid (TA group) or placebo (PL group) topically before sternal closure. Groups were comparable with respect to all preoperative and intraoperative variables. Postoperative bleeding, transfusion requirements and hematologic parameters were evaluated. RESULTS: Postoperative bleeding within first 12-h period (AP group 433+/-294 [350; 360]ml, TA group 391+/-255 [350; 305]ml, PL group 613+/-505 [525; 348]ml), as well as cumulative blood loss within 24h (AP group 726+/-432 [640; 525]ml, TA group 633+/-343 [545; 335]ml, PL group 903+/-733 [800; 445]ml), showed statistically significant inter-group differences (both p<0.001). Bleeding rates values were significantly higher in placebo group compared to the groups treated with antifibrinolytic agents (AP and TA groups) concerning both variables. Although TA group showed the lowest values, no statistical differences between TA and AP groups were found. Inter-group difference of blood product requirements was not statistically significant. CONCLUSIONS: Topical use of either tranexamic acid or aprotinin efficiently reduces postoperative bleeding. TA seems to be at least as potent as aprotinin, but potentially safer and with better cost-effectiveness ratio.

Administration, Topical↗